Clinical trials: Cell, Circulating Tumor
Lung Cancer
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking.
- Trial name
- NCT05965557
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Solid Tumor, Adult, Healthy Donors
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers.
- Conditions
- Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
- Trial name
- NCT00571389
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- BioCytics, Inc.
Prostate Cancer
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml).
- Trial name
- NCT03488706
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- CellMaxLife
Lung Cancer, Pulmonary Neoplasm
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
- Trial name
- BioMolCTC (NCT06546007)
- Testing
- CTC-DNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Rarecells Diagnostics SAS
Non-hematologic Cancer
Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
- Trial name
- NCT02586389
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Sequenom, Inc.
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Prostatic Neoplasms
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer.
- Trial name
- NCT04964271
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Breast Neoplasms
Early Detection of Breast Cancer
The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer.
- Trial name
- NCT06043661
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Datar Cancer Genetics Inc
Cancer of the Lung, Lung Cancer
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the…
- Conditions
- Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung
- Trial name
- NCT02715102
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Pathway Genomics
Colorectal Cancer Screening
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
- Trial name
- NCT05127096
- Testing
- FirstSight blood test
- Where
- 15 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CellMax Life
Healthy Volunteers, Breast Cancer, Metastatic
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
The purpose of this clinical study is to demonstrate that the Parsortix™ PC1 system enables the capture and harvest of circulating tumor cells (CTCs) from the peripheral blood of patients with metastatic breast cancer (MBC) and…
- Trial name
- HOMING (NCT03427450)
- Testing
- Blood draw
- Where
- 4 sites in United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Angle plc
Hormone Refractory Prostate Cancer, Prostate Cancer
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy
This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen [PSA] levels) and who were about to start a new line of chemotherapy.
- Trial name
- IMMC-38 (NCT00133900)
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Immunicon
Metastatic Breast Cancer, Breast Cancer
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States.
- Trial name
- NCT02111031
- Where
- 2 sites in United States
- Sponsor
- Janssen Diagnostics, LLC
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Metastatic Prostate Cancer, CTC
Validation of the Prostate Cancer Assay - Beta+Pivotal
The Prostate Cancer Assay performance of Celsee Diagnostics circulating tumor cell (CTC) analysis system will be validated in patients diagnosed with metastatic prostate cancer.
- Trial name
- VPCA-B+PIV (NCT02742259)
- Testing
- Blood Draw
- Sponsor
- Celsee Diagnostics
Lung Cancer, Lung Cancer, Nonsmall Cell
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Conditions
- Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Cancer, Small Cell
- Trial name
- NCT03499678
- Where
- Kazakhstan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Circulating Tumor Cells, CTC
CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System
Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan.
- Trial name
- NCT03013868
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Breast Cancer
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest.
- Trial name
- NCT03511859
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- CellMaxLife